

99TH ADVISORY FORUM
PAPHOS, 04-05 MARCH 2026


CSO-03 – NOVEL STRATEGY FOR ALLERGENICITY RISK ASSESSMENT

Estefanía Noriega Fernández
Chief Scientist Office

MOTIVATION

➤ Allergenicity RA is a **cross-cutting** issue for EFSA Scientific Units/Panels dealing with proteins (**regulated products**)

- To keep up with the rapid pace of food **innovation**
- To ensure food is **safe** for consumption & does not contribute to the **rising burden** of food allergies



MOTIVATION

➤ Allergenicity RA is primarily informed by **2003 Codex Alimentarius guidelines** (“foods from modern biotechnology”)

- Focus on newly expressed proteins (**NEPs**) in GMOs
- Suggest an integrated, **stepwise**, case-by-case approach as no single test can predict allergenicity:

1. Allergenicity of protein source



2. Amino acid sequence homology



3. Resistance to pepsin digestion



4. Specific serum screening



5. Other considerations




While the overall tiered approach remains valid, certain methodologies would benefit from closer alignment with **state-of-the-art** scientific advances



MOTIVATION

Ranking method & screening tools for allergy RA of innovative proteins

(Mills et al., 2024)



EFSA guidance on NF

(EFSA NDA Panel, 2024)
(Laganaro et al., 2025)


Requirements outlined in the guidance	Challenges and knowledge gaps	Future perspectives
<ul style="list-style-type: none"> Characterisation of the novel protein Characterisation of the allergenicity of the novel protein Characterisation of the allergenicity of the novel protein 	<ul style="list-style-type: none"> Need for improved criteria for allergenicity assessment Need for improved criteria for allergenicity assessment Need for improved criteria for allergenicity assessment 	<ul style="list-style-type: none"> Need for improved criteria for allergenicity assessment Need for improved criteria for allergenicity assessment Need for improved criteria for allergenicity assessment
<ul style="list-style-type: none"> Characterisation of the novel protein Characterisation of the allergenicity of the novel protein Characterisation of the allergenicity of the novel protein 	<ul style="list-style-type: none"> Need for improved criteria for allergenicity assessment Need for improved criteria for allergenicity assessment Need for improved criteria for allergenicity assessment 	<ul style="list-style-type: none"> Need for improved criteria for allergenicity assessment Need for improved criteria for allergenicity assessment Need for improved criteria for allergenicity assessment
<ul style="list-style-type: none"> Characterisation of the novel protein Characterisation of the allergenicity of the novel protein Characterisation of the allergenicity of the novel protein 	<ul style="list-style-type: none"> Need for improved criteria for allergenicity assessment Need for improved criteria for allergenicity assessment Need for improved criteria for allergenicity assessment 	<ul style="list-style-type: none"> Need for improved criteria for allergenicity assessment Need for improved criteria for allergenicity assessment Need for improved criteria for allergenicity assessment

Allergenicity RA of innovative proteins – Training for EFSA staff



(NP/EFSA/NIF/2025/01)


Effect of processing on protein safety



(Martinez et al., 2024)


Development needs for allergenicity & protein safety assessments

(EFSA GMO Panel, 2022)




Safety assessment of newly expressed proteins in GM plants

(EFSA GMO Panel, 2025)



MOTIVATION



MOTIVATION

New editorial | EFSA's Research & Innovation Needs



CSO

Published 05/05/2025 · 1 min read

A [new editorial](#) has been published, highlighting key **research and innovation (R&I) needs** to support EFSA's regulatory science. The focus areas include:

- Omics technologies
- Gut microbiome
- New approach methodologies (NAMs)
- Allergenicity risk assessment
- Aggregate exposure assessment
- Environmental risk assessment (ERA)

The document highlights **emerging challenges and opportunities**, calls for **transdisciplinary research**, and emphasizes the interconnectedness of **human, animal, plant, and environmental health**.

This resource is valuable for stakeholders and funders in shaping future research and funding initiatives related to food safety.



Advancing EFSA's regulatory science: Updated research and...



Share on LinkedIn



MOTIVATION

Call for revision of allergenicity RA methodologies to remain F4P and better inform decision-making



EFSA'S STRATEGIC PRIORITIES (EFSA Strategy 2027)

EOR
1.1.1

↑ Quality and efficiency of RA
(regulated products)



EOR
2.1.3

↑ Capacity for future RA
challenges



MOTIVATION

Call for revision of allergenicity RA methodologies to remain F4P and better inform decision-making



EFSA Scientific Opinions on the safety of **insects** as **Novel Foods**



EFSA NDA Panel: *“Research to be undertaken on **allergenicity** of insects, including **cross-reactivity**”*



Ongoing dialogue with **DG SANTE** on allergenicity of innovative proteins



OBJECTIVES

01. Open-source *in silico* prediction/ appraisal tool for clinical cross-reactivity

- ▶ Curated allergen **database** ranked according to **clinical relevance**
- ▶ **Integrated** phylogenetics, sequence homology and structural similarity



Novel strategy for F4P allergenicity RA

- Reliability & speed of RA
- Simplification & harmonisation



02. Open-source *in silico* prediction/ appraisal tool for *de novo* sensitisation

- ▶ Modelling of protein **binding** capacity to antigen-presenting cells (HLA)
- ▶ Other aspects informing on sensitisation capacity (e.g., **molecular patterns**)

03. Verification of *in silico* predictions and future prospects of *in silico* tools

- ▶ Generation of **experimental** *in vitro* and *in vivo* (human or animal) data
- ▶ **Impact** of protein digestibility, food matrix and processing on protein properties & allergenic potential



Better-informed decision-making



04. Novel strategy for allergenicity RA

- ▶ **Thresholds** of allergological concern
- ▶ **Systematic tiered approach:**
 - Clinically-relevant cross-reactivity
 - *De novo* sensitisation
 - Decision-making framework (criteria for each tier)



PROJECT TIMELINE



EXPECTED CALL LAUNCH
March 2026



PIN ON EU FUNDING & TENDERS PORTAL

SINGLE FRAMEWORK CONTRACT
(€1.3 M)



SC1 – €160k (6 m)

Inception report

Literature review on **future prospects** for *in silico* prediction tools

SC2 – €430k (16 m)

Allergen **database** (clinical relevance)

Mathematical **models for de novo** sensitisation potential

Experimental in vitro/in vivo testing

SC3 – €430k (16 m)

In silico prediction/appraisal **tool for clinical cross-reactivity**

In silico prediction/appraisal **tool for de novo sensitisation**

Experimental in vitro/in vivo testing

SC4 – €280k (10 m)

Thresholds of allergological concern

Systematic tiered approach (decision-making framework)



EFSA RESOURCES

PROJECT STEERING COMMITTEE

- Ana Afonso (Project Owner)
- Claudia Heppner (Solution Provider)
- Claudia Paoletti (IRMA Programme Manager)
- Ioannis Marios Sarikas (IRMA Programme Officer)
- Estefanía Noriega Fernández (Business Manager)

INVOLVED UNITS

- NIF (Novel Foods, GMO)
- FIP (Food enzymes, Food Additives)
- FEEDCO (Feed additives)
- PREV
- KNOW
- IDATA
- CSO

CONTRIBUTORS

- Alejandra Muñoz González (ISA expert)
- Manola Sulollari (Project Manager)
- Antonio Fernández Dumont (Author)
- Gorgias Garofalakis (Author)
- Carolina Roperro (Support)

STAY CONNECTED

SUBSCRIBE TO

efsa.europa.eu/en/news/newsletters
efsa.europa.eu/en/rss
[Careers.efsa.europa.eu](https://careers.efsa.europa.eu) – job alerts



LISTEN TO OUR PODCAST

Science on the Menu – Spotify, Apple Podcast and YouTube



FOLLOW US ON BLUESKY

[@efsa.bsky.social](https://bsky.app/profile/efsa.bsky.social)
[@efsa-animals.bsky.social](https://bsky.app/profile/efsa-animals.bsky.social) [@efsa-plants.bsky.social](https://bsky.app/profile/efsa-plants.bsky.social)



FOLLOW US ON LINKEDIN

[Linkedin.com/company/efsa](https://www.linkedin.com/company/efsa)



FOLLOW US ON INSTAGRAM

[@one_healthenv_eu](https://www.instagram.com/one_healthenv_eu)



CONTACT US

efsa.europe.eu/en/contact/askefsa

